BioLife Solutions Inc (NASDAQ:BLFS) VP Todd Berard sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $17.47, for a total value of $52,410.00. Following the completion of the transaction, the vice president now owns 44,074 shares of the company’s stock, valued at approximately $769,972.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Todd Berard also recently made the following trade(s):

  • On Wednesday, May 15th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The shares were sold at an average price of $16.96, for a total value of $50,880.00.
  • On Monday, April 15th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The shares were sold at an average price of $17.56, for a total value of $52,680.00.

Shares of NASDAQ:BLFS opened at $16.56 on Friday. The firm has a market cap of $322.41 million, a price-to-earnings ratio of 100.88 and a beta of 1.46. BioLife Solutions Inc has a 12-month low of $9.15 and a 12-month high of $26.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.50 and a quick ratio of 12.99.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported $0.03 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.03. The business had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $5.67 million. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%. As a group, research analysts anticipate that BioLife Solutions Inc will post 0.13 EPS for the current year.

A number of large investors have recently made changes to their positions in BLFS. Bank of New York Mellon Corp bought a new stake in shares of BioLife Solutions in the 3rd quarter worth about $835,000. Vanguard Group Inc. grew its holdings in shares of BioLife Solutions by 43.1% in the 3rd quarter. Vanguard Group Inc. now owns 447,984 shares of the medical equipment provider’s stock worth $7,839,000 after purchasing an additional 134,869 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of BioLife Solutions by 7.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 20,515 shares of the medical equipment provider’s stock worth $247,000 after purchasing an additional 1,400 shares during the last quarter. GSA Capital Partners LLP grew its holdings in shares of BioLife Solutions by 21.1% in the 4th quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 2,400 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of BioLife Solutions by 19.2% in the 4th quarter. Northern Trust Corp now owns 49,729 shares of the medical equipment provider’s stock worth $598,000 after purchasing an additional 8,003 shares during the last quarter. Institutional investors and hedge funds own 45.76% of the company’s stock.

A number of research analysts have issued reports on the company. BidaskClub upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Tuesday, March 19th. ValuEngine upgraded BioLife Solutions from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 19th. Zacks Investment Research cut BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Tuesday, March 19th. Finally, Maxim Group set a $24.00 price objective on BioLife Solutions and gave the company a “buy” rating in a research note on Wednesday, May 22nd. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $17.80.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Story: Dividend Stocks – Are They Right For You?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.